Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : BIKO: BICO -- Ignore unavailable to you. Want to Upgrade?

To: George K. who wrote (2)	6/4/2001 12:55:43 AM
From: afrayem onigwecher	Respond to of 28

BICO Subsidiary, ViaCirq, and Veterans Medical Center Enter Into ThermoChem(TM) HT System Evaluation Agreement PITTSBURGH, May 23, 2001 /PRNewswire via COMTEX/ -- BICO, Inc. (OTC Bulletin Board: BIKO chart, msgs) subsidiary, ViaCirq, Inc., a leading developer and marketer of extracorporeal hyperthermia medical devices, announced today that it has entered into an agreement with a Veterans Affairs Medical Center (VAMC) to use and evaluate the ThermoChem(TM) HT System as part of an operative procedure to deliver intraperitoneal hyperthermia (IPH). The Evaluation Agreement requires the VA Medical Center to purchase IPH procedure kits for each treatment. The first IPH treatment, using the ThermoChem HT System, was administered on May 14, 2001. VAMC management will discuss the feasibility of whether this surgical procedure, utilizing the ThermoChem HT System, can be marketed to other VA Medical Centers regionally or nationally. IPH is used as an adjunctive therapy with surgery and chemotherapy in treatment of advanced gastrointestinal and ovarian cancer. The use of IPH treatments, like the one performed at the VAMC, have been shown to improve both survival and quality of life for patients with these advanced stage cancers. ViaCirq received FDA clearance to market the ThermoChem HT System last year. The ThermoChem HT System is used to raise the core temperature of the abdominal cavity to the desired target temperature in the 41C (105.8F) to 42C (107.6F) range by continuously bathing the abdominal cavity with circulating sterile solution. BICO, Inc. has its corporate offices in Pittsburgh, PA and is involved in the development and manufacture of biomedical devices and environmental solutions. BICO's subsidiary, ViaCirq, Inc., also located in Pittsburgh, PA, is committed to becoming the worldwide market leader in developing, manufacturing and marketing leading-edge hyperthermia products and services of the highest quality and value. FOR FURTHER INFORMATION, CONTACT: Investors Media Diane McQuaide Susan Taylor 1-412-429-0673 phone 1-412-429-0673 phone 1-412-279-9690 fax 1-412-279-5041 fax INVESTOR RELATIONS NEWSLINE NUMBER: 1-800-357-6204 www.bico.com This press release contains statements of a forward looking nature. Shareholders and potential investors are cautioned that such statements are predictions and actual events or results may vary significantly. MAKE YOUR OPINION COUNT - Click Here tbutton.prnewswire.com Source: BICO, Incorporated Contact: Investors: Diane McQuaide, 412-429-0673, or fax 412-279-9690, or Media: Susan Taylor, 412-429-0673, or 412-279-5041, both of BICO URL: bico.com News provided by COMTEX User Agreement